Page 126 - Read Online

Jiang et al. J Transl Genet Genom 2021;5:323-40 https://dx.doi.org/10.20517/jtgg.2021.21 Page 339

72. Paik JH, Jang JY, Jeon YK, et al. MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor
suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 2011;17:4761-71. DOI PubMed
73. Liang L, Nong L, Zhang S, et al. The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in
extranodal NK/T-cell lymphoma, nasal type. J Exp Clin Cancer Res 2014;33:7. DOI PubMed PMC
74. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of
tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009;114:3265-75. DOI PubMed
75. Baytak E, Gong Q, Akman B, Yuan H, Chan WC, Küçük C. Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs
in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1. Tumour Biol 2017;39:1010428317701648. DOI
PubMed
76. Wang L, Yang J, Wang HN, et al. LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell
lymphoma. Theranostics 2021;11:925-40. DOI PubMed PMC
77. Liu Q, Ran R, Wu Z, et al. Long Non-coding RNA X-inactive specific transcript mediates cell proliferation and intrusion by
modulating the miR-497/Bcl-w axis in extranodal natural killer/T-cell lymphoma. Front Cell Dev Biol 2020;8:599070. DOI PubMed
PMC
78. Zhu L, Zhang X, Fu X, et al. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug
sensitivity in natural killer/T-cell lymphoma. J Cell Biochem 2019;120:12628-37. DOI PubMed
79. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
DOI PubMed
80. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune
system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7. DOI PubMed PMC
81. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J
Med 2015;372:311-9. DOI PubMed PMC
82. Herbst RS, Baas P, Kim D, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell
lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. DOI PubMed
83. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl
J Med 2015;373:23-34. DOI PubMed PMC
84. André T, Shiu KK, Kim TW, et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med 2020;383:2207-18. DOI PubMed
85. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell
lymphoma failing l-asparaginase. Blood 2017;129:2437-42. DOI PubMed
86. Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol
2018;11:15. DOI PubMed PMC
87. Lim JQ, Huang D, Tang T, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-
killer/T cell lymphoma. Leukemia 2020;34:3413-9. DOI PubMed PMC
88. Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-
label phase 2 study. Blood 2020;136:2754-63. DOI PubMed
89. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018;362:k3529.
DOI PubMed PMC
90. Kanno H, Kojya S, Li T, Ohsawa M, Nakatsuka S, et al. Low frequency of HLA-A*0201 allele in patients with Epstein-Barr virus-
positive nasal lymphomas with polymorphic reticulosis morphology. Int J Cancer 2000;87:195-9. PubMed
91. Tian XP, Ma SY, Young KH, et al. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-
cell lymphoma. Blood ;2021:452-63. DOI PubMed
92. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92. DOI PubMed
93. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer
2016;16:789-802. DOI PubMed
94. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as
nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996;68:285-90. DOI PubMed
95. Xu ZG, Iwatsuki K, Oyama N, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous
natural killer/T-cell lymphomas. Br J Cancer 2001;84:920-5. DOI PubMed PMC
96. Kang MS, Kieff E. Epstein-Barr virus latent genes. Exp Mol Med 2015;47:e131. DOI PubMed PMC
97. Humme S, Reisbach G, Feederle R, et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several
thousandfold. Proc Natl Acad Sci U S A 2003;100:10989-94. DOI PubMed PMC
98. Okuno Y, Murata T, Sato Y, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat
Microbiol 2019;4:404-13. DOI PubMed
99. Nagamine M, Takahara M, Kishibe K, et al. Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma.
Virus Genes 2007;34:47-54. DOI PubMed
100. Menon V, Povirk LF. XLF/Cernunnos: An important but puzzling participant in the nonhomologous end joining DNA repair
pathway. DNA Repair (Amst) 2017;58:29-37. DOI PubMed PMC
101. Bauer CC, Aberle SW, Popow-Kraupp T, Kapitan M, Hofmann H, Puchhammer-Stöckl E. Serum Epstein-Barr virus DNA load in
primary Epstein-Barr virus infection. J Med Virol 2005;75:54-8. DOI PubMed
102. Zhang Y, Ohyashiki JH, Takaku T, Shimizu N, Ohyashiki K. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host